CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

Moolky Nagabhushan; Casey M. Miller; Theresa P. Pretlow; Joseph M. Giaconia; Nancy L. Edgehouse; Stuart Schwartz; Hsing Jien Kung; Ralph W. De Vere White; Paul H. Gumerlock; Martin I. Resnick; Saeid B. Amini; Thomas G. Pretlow

CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

Moolky Nagabhushan, Casey M. Miller, Theresa P. Pretlow, Joseph M. Giaconia, Nancy L. Edgehouse, Stuart Schwartz, Hsing Jien Kung, Ralph W. De Vere White, Paul H. Gumerlock, Martin I. Resnick, Saeid B. Amini, Thomas G. Pretlow

Research output: Contribution to journal › Article › peer-review

222 Citations (Scopus)

Abstract

Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.

Original language	English
Pages (from-to)	3042-3046
Number of pages	5
Journal	Cancer Research
Volume	56
Issue number	13
Publication status	Published - Jul 1 1996
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., De Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., & Pretlow, T. G. (1996). CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Research, 56(13), 3042-3046.

@article{222a8a09b8144e2db5d075ccc1857df6,

title = "CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar",

abstract = "Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.",

author = "Moolky Nagabhushan and Miller, {Casey M.} and Pretlow, {Theresa P.} and Giaconia, {Joseph M.} and Edgehouse, {Nancy L.} and Stuart Schwartz and Kung, {Hsing Jien} and {De Vere White}, {Ralph W.} and Gumerlock, {Paul H.} and Resnick, {Martin I.} and Amini, {Saeid B.} and Pretlow, {Thomas G.}",

year = "1996",

month = jul,

day = "1",

language = "English",

volume = "56",

pages = "3042--3046",

journal = "Journal of Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "13",

}

TY - JOUR

T1 - CWR22

T2 - The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

AU - Nagabhushan, Moolky

AU - Miller, Casey M.

AU - Pretlow, Theresa P.

AU - Giaconia, Joseph M.

AU - Edgehouse, Nancy L.

AU - Schwartz, Stuart

AU - Kung, Hsing Jien

AU - De Vere White, Ralph W.

AU - Gumerlock, Paul H.

AU - Resnick, Martin I.

AU - Amini, Saeid B.

AU - Pretlow, Thomas G.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.

AB - Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold.

UR - http://www.scopus.com/inward/record.url?scp=0029942883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029942883&partnerID=8YFLogxK

M3 - Article

C2 - 8674060

AN - SCOPUS:0029942883

SN - 0008-5472

VL - 56

SP - 3042

EP - 3046

JO - Journal of Cancer Research

JF - Journal of Cancer Research

IS - 13

ER -

CWR22: The first human prostate cancer xenograft with strongly: Androgen-dependent and relapsed strains both in vivo and in soft agar

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this